(1 ) regarding a strong interaction between serum gammaglutamyltransferase (GGT) activity and body mass index (BMI) and their effect on the risk of prevalent diabetes. The authors found that BMI is associated with prevalent diabetes only among individuals with highnormal GGT, suggesting that GGT determination can be useful in clinical settings for identifying individuals at high risk for diabetes.
Given the scientific and clinical importance of an interaction between obesity and GGT in predicting diabetes, we investigated possible interactions between BMI and GGT in predicting poor glycemic control and common comorbidities of diabetes. Therefore, we assessed whether the association of BMI with hypertension, dyslipidemia, and poor glyce- 2 ). Although the associations of BMI with different outcome measures were significant, the associations varied remarkably by serum GGT activity ( Table 1) . As serum GGT activity increased, the association of BMI with dyslipidemia and glycemic control strengthened (P value for interaction Ͻ0.001); in contrast, the association between BMI and hypertension did not substantially change across GGT categories. For example, within the lowest GGT quartile, BMI was not associated with dyslipidemia or worse glycemic control, in contrast to the highest GGT quartile, wherein the prevalence rates were 60%-78.5% for dyslipidemia and 50.4%-72.4% for glycemic control, respectively. Notably, these results were observed after adjustment for sex, age, and diabetes duration and treatment.
Our findings suggest that in people with type 2 diabetes, BMI is associated with worse glycemic control and dyslipidemia only among those with high-normal GGT, but not in those with low-normal GGT. These findings, although only correlative in nature, complement the cross-sectional observations by Lim et al. (1 ) , suggesting that the association of BMI with type 2 diabetes and its related metabolic disorders remarkably varied with serum GGT activity, and that obesity itself may not be a sufficient risk factor for developing diabetes, dyslipidemia, or worse glycemic control.
The associations between GGT activity and diabetes and its related comorbidities may possibly be explained by some underlying biological mechanisms such as enhanced oxidative stress, insulin resistance, and fatty liver.
Markers of liver fat such as serum GGT activity have been shown in prospective studies to predict type 2 diabetes, insulin resistance, dyslipidemia, and cardiovascular disease independent of obesity (4 ). Moreover, obesity appears to be unnecessary to the occurrence of insulin resistance in humans, because severe insulin resistance also characterizes patients lacking subcutaneous fat, such as those with lipodystrophy. A close linear relationship exists between liver fat content and direct measures of hepatic insulin resistance (4 ). The fatty liver thus might help to explain why some but not all obese individuals are insulin resistant and why even lean individuals may be insulin resistant and thereby at risk of developing type 2 diabetes and its related metabolic dis- 
The authors of the article cited above respond:
To the Editor: We read with interest the 2 letters addressing our recent article on the interactive effects of obesity and serum ␥-glutamyltransferase (GGT) on the risk of type 2 diabetes. We reported that obesity, a well-established risk factor of type 2 diabetes, was not associated with type 2 diabetes among the approximately 50% of participants with low-normal serum GGT, whereas obesity was associated with risk of diabetes in the other half of participants who had high-normal serum GGT.
Targher et al.'s cross-sectional findings among type 2 diabetes patients, reported above, appear to support our findings, despite a study purpose and population that differed from ours. Targher et al. reported that associations between obesity and the risk of dyslipidemia and poor glycemic control were observed only among type 2 diabetic patients with high-normal and abnormal GGT, although the association between obesity and hypertension was seen at all GGT concentrations. Lippi et al., in a methodologically more limited study restricted to hospital laboratory values, failed to find any difference in the relation of hypertriglyceridemia to increased fasting plasma glucose across concentrations of serum GGT, although serum GGT itself was associated with both type 2 diabetes and hypertriglyceridemia. No measure of adiposity was available. Because the interaction of serum GGT with obesity may have a specific meaning in terms of cause and/or pathophysiology of type 2 diabetes (see below), Lippi et al.'s study of the interaction between serum GGT and hypertriglyceridemia in predicting concurrent type 2 diabetes may not be pertinent to our findings.
The authors of both letters interpreted serum GGT largely as a marker of fatty liver or oxidative stress. Although both these correlates of serum GGT could be involved, our current thinking is that a more important consideration may be the role of serum GGT as a cumulative biomarker of exposure to xenobiotics. Cellular GGT is necessary to metabolize certain xenobiotics (1 ) . We have recently reported dose-response relations of serum or urinary concentrations of environmental pollutants [such as lead or cadmium (2 ) or persistent organic pollutants (POPs) (3 )] with serum GGT within its reference interval in the general population. Among various xenobiotics, in relation to type 2 diabetes, POPs stored in adipose tissues may be the most relevant. Parallel to the interaction between obesity and serum GGT on the risk of type 2 diabetes and insulin resistance, there were interactions between obesity and serum concentrations of POPs associated with the risk of type 2 diabetes (4 ). Thus, we hypothesized that the risk of type 2 diabetes would be increased among obese persons with substantial amounts of POPs in their adipose tissue, which are reflected as high-normal serum GGT, but that the risk of type 2 diabetes might not be increased among obese persons without substantial amounts of POPs in their adipose tissue, reflected as low-normal serum GGT.
Broadly speaking, this interpretation may not contradict the prevailing concept of serum GGT as a marker of fatty liver, because POP exposure may increase the risk of fatty liver as well as type 2 diabetes; in fact, serum concentrations of POPs were also associated with the prevalence of metabolic syndrome in the US general population (5 ). Etiologically, however, it may be important to determine whether serum GGT predicts clinical outcomes as an exposure marker of xenobiotics such as POPs or as a marker of fatty liver itself. In fact, components related to metabolic syndrome, such as dyslipidemia and/or fatty liver, may be regarded as outcomes consequent to POP exposure (5 ), similar to type 2 diabetes. In this sense, it is questionable whether the interaction between serum GGT and triglycerides on the risk of type 2 diabetes, which was tested in Lippi et al.'s laboratory data set, reflects the same biological mechanism as does the interaction of serum GGT with obesity. However, in Targher 
